Mr. George Lin, a healthcare veteran brings with him over 20 years of investment banking and legal experience working with numerous private and public companies globally.
Hua Medicine, a leading clinical stage biotech company in Shanghai, announced today positive results in the first-ever successful Phase 2 monotherapy trial of a novel drug class called glucokinase activators (GKA).
The Phase II clinical trial was initiated exactly one year ago on September 22, 2015 with 258 Chinese Type 2 Diabetes patients participating in the drug treatment study.
"Hua Medicine is one of the most innovative healthcare companies in Asia. It has the first new biological mechanism, first-in-class diabetes drug to be developed entirely in China – from preclinical to late-stage clinical trials.
Hua Medicine announced today its third successful clinical trial of lead program HMS5552, a novel glucokinase activator (GKA) treatment for Type 2 diabetes (T2DM).
Continuing its momentum after raising $25 million in Series B financing earlier this year, Hua Medicine, an innovative biotechnology company in Shanghai, has announced the filing of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA)
Copyright © 2019 Hua Medicine, All Rights Reserved沪ICP备14036654号